Open Access

Variant Philadelphia t(X;9;22)(q22?;q34;q11.2) can be successfully treated with second generation tyrosine kinase inhibitors: A case report and literature review

  • Authors:
    • Ana Iglesias
    • Raluca Oancea
    • Carmen Cotarelo
    • Eduardo Anguita
  • View Affiliations

  • Published online on: August 9, 2021     https://doi.org/10.3892/br.2021.1459
  • Article Number: 83
  • Copyright: © Iglesias et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chronic myeloid leukemia (CML) is characterized by the reciprocal translocation between chromosomes 9 and 22: t(9;22)(q34;q11). However, 5‑10% of patients with CML have complex variant translocations involving at least a third chromosome; only a few cases affect the X chromosome. Therefore, the data available regarding their features and the response to treatment is limited. In the present report, a case of a variant Philadelphia translocation t(X;9;22)(q22?;q34;q11.2) identified in a 51‑year‑old female with a newly diagnosed CML is described. The patient was treated with nilotinib. A major molecular response was observed after 12 months of starting treatment. Deep molecular response was obtained 20 months later and maintained after the 110‑month follow‑up. Additionally, a literature review was performed, with the aim of comprehending the complex clinical and biological characteristics of CML cytogenetic variants involving the X chromosome.
View Figures
View References

Related Articles

Journal Cover

October-2021
Volume 15 Issue 4

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Iglesias A, Oancea R, Cotarelo C and Anguita E: Variant Philadelphia t(X;9;22)(q22?;q34;q11.2) can be successfully treated with second generation tyrosine kinase inhibitors: A case report and literature review. Biomed Rep 15: 83, 2021.
APA
Iglesias, A., Oancea, R., Cotarelo, C., & Anguita, E. (2021). Variant Philadelphia t(X;9;22)(q22?;q34;q11.2) can be successfully treated with second generation tyrosine kinase inhibitors: A case report and literature review. Biomedical Reports, 15, 83. https://doi.org/10.3892/br.2021.1459
MLA
Iglesias, A., Oancea, R., Cotarelo, C., Anguita, E."Variant Philadelphia t(X;9;22)(q22?;q34;q11.2) can be successfully treated with second generation tyrosine kinase inhibitors: A case report and literature review". Biomedical Reports 15.4 (2021): 83.
Chicago
Iglesias, A., Oancea, R., Cotarelo, C., Anguita, E."Variant Philadelphia t(X;9;22)(q22?;q34;q11.2) can be successfully treated with second generation tyrosine kinase inhibitors: A case report and literature review". Biomedical Reports 15, no. 4 (2021): 83. https://doi.org/10.3892/br.2021.1459